| Market Cap | 229.78M | P/E | - | EPS this Y | 58.70% | Ern Qtrly Grth | - |
| Income | -153.05M | Forward P/E | -1.54 | EPS next Y | 33.90% | 50D Avg Chg | -48.00% |
| Sales | 1.76M | PEG | 0.00 | EPS past 5Y | - | 200D Avg Chg | -61.00% |
| Dividend | N/A | Price/Book | 4.33 | EPS next 5Y | 294.10% | 52W High Chg | -77.00% |
| Recommedations | 2.20 | Quick Ratio | 2.37 | Shares Outstanding | 37.53M | 52W Low Chg | 34.00% |
| Insider Own | 21.78% | ROA | -66.96% | Shares Float | 25.82M | Beta | 0.32 |
| Inst Own | 34.33% | ROE | - | Shares Shorted/Prior | 626.14K/1.49M | Price | 7.88 |
| Gross Margin | 24.20% | Profit Margin | - | Avg. Volume | 2,705,837 | Target Price | 8.25 |
| Oper. Margin | -4,151.72% | Earnings Date | Aug 12 | Volume | 1,419,617 | Change | 5.07% |
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
| Canaccord Genuity | Buy | Jun 27, 24 |
| HC Wainwright & Co. | Buy | May 10, 24 |
| HC Wainwright & Co. | Buy | Apr 23, 24 |
| HC Wainwright & Co. | Buy | Mar 18, 24 |
| Canaccord Genuity | Buy | Mar 14, 24 |
| B of A Securities | Buy | Mar 13, 24 |
| UBS | Neutral | Feb 21, 24 |
| HC Wainwright & Co. | Buy | Nov 15, 23 |
| HC Wainwright & Co. | Buy | Oct 31, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Mehta Vimal | CEO and President CEO and President | Jun 14 | Sell | 21.22 | 60,000 | 1,273,200 | 39,903 | 06/16/23 |
| Mehta Vimal | CEO and President CEO and President | Jun 14 | Option | 0.41 | 60,000 | 24,600 | 69,903 | 06/16/23 |
| Steinhart Richard I | Chief Financial Offi.. Chief Financial Officer | May 14 | Sell | 27.17 | 5,000 | 135,850 | 1,500 | 05/16/23 |
| Rodriguez Javier | See Remarks See Remarks | May 14 | Sell | 27.32 | 1,785 | 48,766 | 4,350 | 05/16/23 |
| Nandabalan Krishnan | Director Director | Apr 06 | Sell | 17.32 | 60,000 | 1,039,200 | 04/10/23 | |
| Nandabalan Krishnan | Director Director | Apr 06 | Option | 0.41 | 60,000 | 24,600 | 60,000 | 04/10/23 |
| Mehta Vimal | CEO and President CEO and President | Mar 20 | Sell | 19 | 64,500 | 1,225,500 | 15,894 | 03/22/23 |
| Mehta Vimal | CEO and President CEO and President | Mar 20 | Option | 0.41 | 60,000 | 24,600 | 45,894 | 03/22/23 |
| Yocca Frank | Chief Scientific Off.. Chief Scientific Officer | Jan 20 | Sell | 30.00 | 50,000 | 1,500,000 | 8,397 | 01/24/23 |
| O'Neill Vincent | Chief Medical Office.. Chief Medical Officer | Jan 20 | Sell | 30 | 29,713 | 891,390 | 01/24/23 | |
| O'Neill Vincent | Chief Medical Office.. Chief Medical Officer | Jan 20 | Option | 0.41 | 29,713 | 12,182 | 29,713 | 01/24/23 |
| Nandabalan Krishnan | Director Director | Jan 04 | Sell | 22.26 | 60,000 | 1,335,600 | 01/06/23 | |
| Nandabalan Krishnan | Director Director | Jan 04 | Option | 0.41 | 60,000 | 24,600 | 25,889 | 01/06/23 |
| Mehta Vimal | CEO and President CEO and President | Dec 15 | Option | 0.41 | 60,000 | 24,600 | 39,957 | 12/19/22 |
| Mehta Vimal | CEO and President CEO and President | Dec 15 | Sell | 19.8 | 60,000 | 1,188,000 | 9,957 | 12/19/22 |
| O'Neill Vincent | Chief Medical Office.. Chief Medical Officer | Feb 19 | Option | 5.71 | 25,000 | 142,750 | 25,000 | 02/19/21 |
| O'Neill Vincent | Chief Medical Office.. Chief Medical Officer | Feb 19 | Sell | 55.51 | 25,000 | 1,387,750 | 02/19/21 | |
| Yocca Frank | Chief Scientific Off.. Chief Scientific Officer | Jan 27 | Option | 0.41 | 15,000 | 6,150 | 103,397 | 01/27/21 |